✦ LIBER ✦

Double-blind, crossover placebo controlled trial of selegiline in Parkinson's disease — an interim analysis

✍ Scribed by P. F. Teychenne; S. Parker

Book ID: 114782832
Publisher: John Wiley and Sons
Year: 1989
Tongue: English
Weight: 455 KB
Volume: 80
Category: Article
ISSN: 0001-6314
DOI: 10.1111/j.1600-0404.1989.tb01791.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Colchicine versus placebo in Behçet’s di

Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial

✍ Fereydoun Davatchi; Bahar Sadeghi Abdollahi; Arash Tehrani Banihashemi; Farhad S 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 174 KB

A double blind, placebo controlled, cros

A double blind, placebo controlled, crossover trial of d-ribose in McArdle's disease

✍ Ian C. Steele; Victor H. Patterson; D.Paul Nicholls 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 372 KB

Levodopa improves physical fatigue in Pa

Levodopa improves physical fatigue in Parkinson's disease: A double-blind, placebo-controlled, crossover study

✍ Jau-Shin Lou; Greg Kearns; Theodore Benice; Barry Oken; Gary Sexton; John Nutt 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB

## Abstract We quantitatively investigated the effect of carbidopa/levodopa (25/100) on physical fatigue during finger tapping and force generation in a double‐blind, placebo‐controlled crossover study. Parkinson's disease (PD) subjects were randomly assigned to carbidopa/levodopa or placebo for Vi

Donepezil for dementia in Parkinson's di

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

✍ Ravina, B 📂 Article 📅 2005 🏛 BMJ Publishing Group 🌐 English ⚖ 90 KB

Selegiline (1-deprenyl) and low-dose lev

Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease A double-blind crossover trial.

✍ J. Presthus; J. Berstad; K. Lien 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease

✍ Kitty K. Wong; Jane E. Alty; Amanda G. Goy; Sanjay Raghav; David C. Reutens; Pet 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 565 KB

## Abstract ## Background: This randomized double blind, placebo‐controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease. ## Methods: Sixteen participants with levodopa‐induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments s